Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s240. https://doi.org/10.25251/skin.7.supp.240